{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:32:16Z","timestamp":1740130336261,"version":"3.37.3"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Zenyaku Kogyo, Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This phase II clinical trial evaluated feasibility and tolerability of 90-minute rituximab infusion and a concentration of 4\u00a0mg\/mL rituximab infusion in Japanese patients with previously untreated follicular lymphoma or diffuse large B-cell lymphoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Treatment was rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone. In cycle 1, rituximab at a dose of 375\u00a0mg\/m2 (4\u00a0mg\/mL) was administered at the standard infusion rate stipulated in the package insert. On confirmed tolerance of rituximab, patients received 90-minute infusion in second and subsequent cycles. The primary endpoint was incidence of grade 3 or higher infusion-related reactions during 90-minute rituximab infusion in cycle 2 of rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All 32 patients (median age 61.5\u00a0years, 16 males, 24 with diffuse large B-cell lymphoma) completed the prescribed six or eight\u00a0cycles of treatment. One patient withdrew consent after cycle 1, and another developed grade 2 erythema and continued receiving 4\u00a0mg\/mL at the standard infusion rate for cycle 2. The remaining 30 patients received 90-minute rituximab infusion; 28 (93.3%) completed cycle 2 at the scheduled infusion rate and dosage. No grade 3 or higher infusion-related reactions were associated with a concentration of 4\u00a0mg\/mL rituximab dose or 90-min rituximab infusion in cycle 2. The most common infusion-related reaction symptoms were pruritus, hypertension and oropharyngeal discomfort. During the study, toxicities and adverse events were as expected, with no new safety signals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>High-concentration dosing (4\u00a0mg\/mL) and 90-minute infusion of rituximab are feasible and tolerable in Japanese patients with previously untreated follicular lymphoma or diffuse large B-cell lymphoma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial number<\/jats:title>\n                  <jats:p>JapicCTI-173\u2009663.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad193","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T17:23:42Z","timestamp":1706203422000},"page":"444-451","source":"Crossref","is-referenced-by-count":0,"title":["A phase II Japanese trial of 90-minute rituximab infusion for untreated B-cell lymphoma"],"prefix":"10.1093","volume":"54","author":[{"given":"Toko","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Hematology\/Cell Therapy, Aichi Cancer Center Hospital , 1-1, Kanokoden, Chikusa-ku, Nagoya-shi, Aichi 464-8681 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization, Nagoya Medical Center , 4-1-1, Sannomaru, Nagoya-shi, Aichi 460-0001 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-8057","authenticated-orcid":false,"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital , 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Tokai University School of Medicine , 143, Shimokasuya, Isehara-shi, Kanagawa 259-1193 , Japan"},{"name":"Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University , 1-2-3, Kasumi, Minami-ku, Hiroshima-shi, Hiroshima 734-0037 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadahiko","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Gunma Cancer Center , 617\u20111, Takabayashinishicho, Ohta-shi, Gunma 373-0828 , Japan"},{"name":"Department of Hematology, Chiba Tokushukai Hospital , 2-11-1, Takanedai, Funabashi-shi, Chiba 274-0065 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tochigi Cancer Center , 4-9-13, Yonan, Utsunomiya-shi, Tochigi 320-0834 , Japan"},{"name":"Department of Hematology, Sendai Medical Center , 2-11-12, Miyagino, Miyagino-ku, Sendai-shi, Miyagi 983-0045 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Faculty of Science and Engineering, Chuo University , 1-13-27, Kasuga, Bunkyo-ku, Tokyo 112-8551 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4703-1339","authenticated-orcid":false,"given":"Shuhei","family":"Kamiyama","sequence":"additional","affiliation":[{"name":"Department of Prescription Products Development, Zenyaku Kogyo Co., Ltd , 5-6-15, Otsuka, Bunkyo-ku,Tokyo 112-8650 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology , Third Internal Medicine, Faculty of Medicine, , 1-4-12, Kojirakawa-machi, Yamagata-shi,Yamagata 990-8560 , Japan"},{"name":"Yamagata University , Third Internal Medicine, Faculty of Medicine, , 1-4-12, Kojirakawa-machi, Yamagata-shi,Yamagata 990-8560 , Japan"},{"name":"Department of Nursing , Faculty of Health Sciences, , 1-8-1, Kunimi, Aoba-ku, Sendai-shi, Miyagi 981-8522 , Japan"},{"name":"Tohoku Fukushi University , Faculty of Health Sciences, , 1-8-1, Kunimi, Aoba-ku, Sendai-shi, Miyagi 981-8522 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Cancer Center Hospital , 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045 , Japan"},{"name":"Geriatric Health Services Facility Rehabilitation Care Funabashi , 4-8-30, Honcho, Funabashi-shi, Chiba, 273-0005 , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"2024040806012730400_ref1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br J Haematol"},{"key":"2024040806012730400_ref2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"2024040806012730400_ref3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomized phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024040806012730400_ref4","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"},{"key":"2024040806012730400_ref5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"2024040806012730400_ref6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024040806012730400_ref7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2024040806012730400_ref8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MinT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"2024040806012730400_ref9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"key":"2024040806012730400_ref10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"2024040806012730400_ref11"},{"key":"2024040806012730400_ref12","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3109\/10428194.2013.877135","article-title":"Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma","volume":"55","author":"Dakhil","year":"2014","journal-title":"Leuk Lymphoma"},{"author":"Swerdlow","key":"2024040806012730400_ref13","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues"},{"key":"2024040806012730400_ref14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2024040806012730400_ref15","first-page":"1860","article-title":"Report of the committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"2024040806012730400_ref16","first-page":"253","volume-title":"Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994","edition":"9th"},{"key":"2024040806012730400_ref17","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI sponsored international working group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"article-title":"The Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, Japanese translation by JCOG","year":"2017","author":"Japan Clinical Oncology Group (JCOG) [Internet]","key":"2024040806012730400_ref18"},{"key":"2024040806012730400_ref19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s12185-016-2097-9","article-title":"Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden","volume":"104","author":"Igarashi","year":"2016","journal-title":"Int J Hematol"},{"key":"2024040806012730400_ref20","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00520-013-1788-5","article-title":"Predictors of acute adverse events from rapid rituximab infusion","volume":"21","author":"Lang","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/4\/444\/57174396\/hyad193.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/4\/444\/57174396\/hyad193.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T06:01:59Z","timestamp":1712556119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/4\/444\/7589473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,25]]},"published-print":{"date-parts":[[2024,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad193","relation":{},"ISSN":["1465-3621"],"issn-type":[{"type":"electronic","value":"1465-3621"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,1,25]]}}}